Malignant pleural mesothelioma: New hope in the horizon with novel therapeutic strategies

Cancer Treatment Reviews

Volumn 41, Issue 1, 2015, Pages 27-34

  Remon, J ^a   Reguart, N ^b   Corral, J ^c   Lianes, P ^a  

^a HOSPITAL DE MATARÓ   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Chemotherapy; Epidemiology; Immunotherapy; Maintenance; Malignant pleural mesothelioma; Second line

Indexed keywords

ANGIOGENESIS INHIBITOR; APC PROTEIN; APITOLISIB; BEVACIZUMAB; BRCA ASSOCIATED PROTEIN 1; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYTOTOXIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DEFACTINIB; EVEROLIMUS; FOCAL ADHESION KINASE; GANETESPIB; GEMCITABINE; HEAT SHOCK PROTEIN 90; MAMMALIAN TARGET OF RAPAMYCIN; MERLIN; MESOTHELIN; NAVELBINE; NINTEDANIB; PEGARGIMINASE; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PROTEIN KINASE B; SORAFENIB; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; VORINOSTAT; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; GENE MUTATION; HEALTH CARE QUALITY; HUMAN; MAINTENANCE CHEMOTHERAPY; MOLECULARLY TARGETED THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA MESOTHELIOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR MICROENVIRONMENT; LUNG NEOPLASMS; MESOTHELIOMA; PLEURAL NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; PLEURAL NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84919333858     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.10.007     Document Type: Review

References (85)

1. La Vecchia C., Boffetta P. Role of stopping exposure and recent exposure to asbestos in the risk of mesothelioma. Eur J Cancer Prev 2010, 21:227-230.
2. Stayner L., Welch L.S., Lemen R. The worldwide pandemic of asbestos-related disease. Annu Rev Public Health 2013, 34:205-216.
3. Soeberg M.J., Takahashi K., Movahed M., et al. Global patterns in the incidence of malignant mesothelioma, 1988-2002, using data published by the international Agency for Research on Cancer (IARC). J Thorac Oncol 2013, 8(P2.14-007).
4. Park E.K., Takahashi K., Hoshuyama T., et al. Global magnitude of reported and unreported mesothelioma. Environ Health Perspect 2011, 119:514-518.
5. Robinson B. Malignant pleural mesothelioma: an epidemiologic prospective. Ann Cardiothorac Surg 2012, 1:491-496.
6. (Accessed on 18.06.14). http://www.iarc.fr/en/publications/pdfs-online/epi/sp160/.
7. Craighead J.E. Epidemiology of mesothelioma and historical background. Rec Res Cancer Res 2011, 189:13-25.
8. Delgermaa V., Takahasi K., Park E.K., et al. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 2011, 89:716-724.
9. Taioli E., Wolf A.S., Camacho-Rivera M., Flores R.M. Women with malignant pleural mesothelioma have a threefold better survival rate than men. Ann Thorac Surg 2014, 98:1020-1024.
10. Fennell D.A., Gaudino G., O'Byrne K.J., et al. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008, 5:136-147.
11. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
12. van Meerbeeck J.P., Gaafar R., Manegold C., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005, 23:6881-6889.
13. Ceresoli G.L., Castagneto B., Zucali P.A., et al. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer 2008, 99:51-56.
14. Katirtzoglou N., Gkiozos I., Makrilia N., et al. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clin Lung Cancer 2010, 11:30-35.
15. Santoro A., O'Brien M.E., Stahel R.A., et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac. Oncol 2008, 3:756-763.
16. Byrne M.J., Davidson J.A., Musk A.W., et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999, 17:25-30.
17. Nowak A.K., Byrne M.J., Williamson R., et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002, 87:491-496.
18. Ak G., Metintas S., Akarsu M. The effectiveness and safety of platinum based pemetrexed and platinum based gemcitabine treatment in patients with malignant pleural mesothelioma. J Thorac Oncol 2013, 8(P1.14-013).
19. Lee C.W., Murray N., Anderson H., Rao S.C., Bishop W. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer 2009, 64:308-313.
20. Arrieta O., López-Macías D., Mendoza-García V.O., et al. A phase II trial of prolonged, continuous infusión of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesotelioma. Cancer Chemother Pharmacol 2014, 73:975-982.
21. Paz-Ares L.G., de Marinis F., Dediu M., et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer. J Clin Oncol 2013, 31:2895-2902.
22. van den Bogaert D.P., Pouw E.M., van Wijhe G., et al. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol 2006, 1:25-30.
23. Manegold C., Symanowski J., Gatzemeier U., et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005, 16:923-927.
24. Jassem J., Ramlau R., Santoro A., et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008, 26:1698-1704.
25. Jänne P.A., Wozniak A.J., Belani C.P., et al. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol 2006, 1:506-512.
26. Taylor P., Castagneto B., Dark G., et al. Single-agent pemetrexed for chemonaïve and pre-treated patients with malignant pleural mesothelioma: results of an international Expanded Access Program. J Thorac Oncol 2008, 3:764-771.
27. Ceresoli G.L., Zucali P.A., De Vincenzo F., et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer 2011, 72:73-77.
28. Zucali P.A., Simonelli M., Michetti G., et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 2012, 75:360-367.
29. Muers M.F., Stephens R.J., Fisher P., et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008, 371:1685-1694.
30. Zucali P.A., Perrino M., Lorenzi E., et al. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Lung Cancer 2014, 84:265-270.
31. Busacca S., Sheaff M., Arthur K., et al. BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. J Pathol 2012, 227:200-208.
32. Raphael J., Le Teuff G., Hollebecque A., et al. Efficacy of phase I trials in malignant pleural mesothelioma: description of a series of patients in a single institution. Lung Cancer 2014, 85:251-257.
33. Scagliotti G.V., Lo Lacono M., Novello S., et al. Next-generation sequencing in malignant pleural mesothelioma a retrospective study. J Clin Oncol 2014, 32(suppl; abstract 7530).
34. Veresano S., Leo C., Boccardo S., et al. Status of Anaplastic Lymphoma Kinase (ALK) in malignant mesothelioma. Anticancer Res 2014, 34:2589-2592.
35. Ladanyi M., Zauderer M.G., Krug L.M., et al. New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. Clin Cancer Res 2012, 18:4485-4490.
36. Zauderer M.G., Bott M., McMillan R. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations. J Thorac Oncol 2013, 8:1430-1433.
37. Arzt L., Quehenberger F., Halbwedl L., et al. BAP1 protein is a progression factor in malignant pleural mesothelioma. Pathol Oncol Res 2014, 20:145-151.
38. Xu J., Kadariya Y., Cheung M., et al. Germline mutation of BAP1 accelerates development of asbestos-induced malignant mesothelioma. Cancer Res 2014, 74:4388-4397.
39. Landreville S., Agapova O.A., Matatall K.A., et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res 2012, 18:408-416.
40. Krug L.M., Kindler H., Calvert H., et al. VANTAGE 014: Vorinostat in patients with advanced malignant pleural mesothelioma who failed prior pemetrexed and either cisplatin or carboplatin therapy: a phase III, randomized, double-blind, placebo-controlled trial. Eur J Cancer 2011, 47:2-3.
41. Poulikakos O.I., Xiao G.H., Gallagher R., et al. Re-expression of tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 2006, 28:5960-5968.
42. Soria J.C., Gan H.K., Arkeanu H.T., et al. Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in patients with advanced solid tumors. J Clin Oncol 2012, 30(suppl; abstract 3000a).
43. Shapiro I.M., Kolev V.N., Vidal C.M., et al. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med 2014, 6:237ra68.
44. Garland L.L., Ou S.H., Moon J., et al. SWOG 0722: a phase II study of mTOR inhibitor everolimus (RAD 001) in malignant pleural mesothelioma. J Clin Oncol 2012, 30(suppl; abstract 7083).
45. Carracedo A., Ma L., Teruya-Feldstein J., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008, 118:3065-3074.
46. Dolly S., Krug L.M., Wagner J.A., et al. Evaluation of tolerability and anti-tumor activity of GDC0980, an oral PI3K/mTOR inhibitor, administrated to patients with advanced malignant pleural mesothelioma. J Thorac Oncol 2013, 8(MO09.01).
47. Zhou S., Liu L., Li H., et al. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma. Br J Cancer 2014, 110:279-288.
48. Buikhuisen W.A., Burgers J.A., Vincent A.D., et al. Thalidomide versus supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicenter, randomized phase 3 study. Lancet Oncol 2013, 14:543-551.
49. Ceresoli G.L., Zucali P.A., Mencoboni, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer 2013, 109:552-558.
50. Dowell J.E., Dunphy F.R., Taub R.N., et al. A multicentre phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer 2012, 77:567-571.
51. Kindler H.L., Karrison T.G., Gandara D.R., et al. Multicentre, double-blind, placebo controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2012, 30:2509-2515.
52. Zalcman G., Margery J., Scherpereel A., et al. IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma. J Clin Oncol 2012, 30(suppl; TPS7112a).
53. Barlesi F., Scherpereel A., Gorbunova V., et al. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced non-squamous non-small cell lung cancer: updated survival analysis of the AVAPERL randomized phase III trial. Ann Oncol 2014, 25:1044-1052.
54. Reck M., Kaiser R., Mellemgaard A., et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomized controlled trial. Lancet Oncol 2014, 15:143-155.
55. Fujmoto J., Wistuba I.I., Moon J., et al. Biomarker results from a phase I study of cediranib in combination with cisplatin and pemetrexed in chemonaïve patients with malignant pleural mesothelioma (SWOG 0905). J Thorac Oncol 2013, 8(P1.14-009).
56. Garland L.L., Chansky K., Wozniak A.J., et al. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol 2011, 6:1938-1945.
57. Campbell N.P., Kunnavakkam R., Leighl N.B., et al. Cediranib in patients with malignant mesothelioma: a phase II trial of The University of Chicago Phase II Consortium. Lung Cancer 2012, 78:76-80.
58. Papa S., Popat S., Shah R., et al. Phase 2 study of sorafenib in malignant pleural mesothelioma previously treated with platinum-containing chemotherapy. J Thorac Oncol 2013, 8:783-787.
59. Laurie S.A., Gupta A., Chu Q., et al. Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group. J Thorac Oncol 2011, 6:1950-1954.
60. Nowak A.K., Millward M.J., Creany J., et al. Phase II study of intermitent sunitinib maleate as second-line therapy in progressive in malignant pleural mesotelioma. J Thorac Oncol 2012, 7:1449-1456.
61. Nowak A.K., Brown C., Millward M.J., et al. A phase II clinical trial of vascular disrupting agent BNCP105P as second line chemotherapy for advanced malignant pleural mesothelioma. Lung Cancer 2013, 81:422-427.
62. Rossoni G., Gregorc V., Vigano M.G., et al. NGR-hTNF as second-line treatment in malignant pleural mesothelioma (MPM). J Clin Oncol 2012, 30(suppl; abstract 7076).
63. Okamoto J., Mikami I., Tominaga Y., et al. Inhibition of Hsp90 leads to cell arrest and apoptosis in human malignant pleural mesothelioma. J Thorac Oncol 2008, 3:1089-1095.
64. Ramalingam S.S., Goss G.D., Andric Z.G., et al. A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1). J Clin Oncol 2013, 31(suppl; abstract CRA 8007).
65. Szlosarek P.K., Klabatsa A., Pallaska A. In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res 2006, 12:7126-7131.
66. Wojciech P., Peter J., Nolan L., et al. Randomized trial of arginine deprivation with pegylated arginine deaminase in patients with malignant pleural mesothelioma. J Clin Oncol 2014, 32(suppl; abstract 7507):52.
67. Brahmer J.R. Immune checkpoints blockade: the hope for immunotherapy as a treatment of lung cancer. Semin Oncol 2014, 41:126-132.
68. Langer C. Emerging immunotherapies in the treatment of non-small cell lung cancer. The role of immune checkpoints inhibitors. Am J Clin Oncol 2014, Epub ahead of print.
69. Kindler H.L., Zuo Z., Khattri A., et al. T-Cell inflamed phenotype and PDL1 expression in malignant mesothelioma. J Clin Oncol 2014, 32(suppl; abstract 7589).
70. Mansfield A.S., Roden A.C., Peikert T., et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoide histology and poor prognosis. J Thorac Oncol 2014, 97:1036-1040.
71. Cedres S., Ponce S., Zugazagoitia J., et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesotelioma. ESMO 2014, Abstract 1556O-PR.
72. Soria J., Cruz C., Bahelda R., et al. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer additional analysis from clinical study of the engineered antibody MPDL3280A (anti-PDL1). Eur Cancer Cong 2013, Abstract 3408.
73. Calabrò L., Morra A., Fonsatti E., et al. Tremelimumab for patients with chemotherapy resistant advanced malignant pleural mesothelioma: an open-label, single-arm, phase II trial. Lancet Oncol 2013, 14:1104-1111.
74. Calabrò L., Morra A., Fonsatti E., et al. A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients. J Clin Oncol 2014, 32(suppl; abstract 7531).
75. Servais E.L., Colvos C., Rodriguez L., et al. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res 2012, 19:2478-2489.
76. Hassan R., Cohen S.J., Phillips M., et al. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 2010, 16:6132-6138.
77. Hassan R., Jahan T.M., Kindler H.L., et al. Amatuximab, a chimeric monoclonal antibody to mesothelin, in combination with pemetrexed and cisplatin in patients with unresectable pleural mesothelioma: results of a multicenter phase II clinical trial. J Clin Oncol 2012, 30(suppl; abstract 7030).
78. Maltzman J.D., Wallin B.A., Gupta A., et al. Exposure-response relationship of amatuximab in combination with pemetrexed and cisplatin in patients with unresectable pleural mesotelioma. J Thorac Oncol 2013, 8(O22.05).
79. Hassan R., Alley E., Kindler H., et al. Anti-mesothelin vaccine CRS-207 plus chemotherapy as front-line treatment for malignant pleural mesothelioma. J Clin Oncol 2014, (suppl; abstract 7532).
80. Zhang J., Qiu S., Zhang Y., et al. Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P. Anticancer Res 2012, 32:5151-5158.
81. Hassan R., Miller A.C., Sharon E., et al. Major cancer regressions in mesothelioma after treatment with anti-mesothelin immunotoxin and immune suppression. Sci Transl Med 2013, 5(208):208ra147.
82. Hassan R., Sharon E., Thomas A., et al. Phase I study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer 2014, 120:3311-3319.
83. Hegmans J.P., Hemmes A., Hammad H., et al. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J 2006, 27:1086-1095.
84. Fridlender Z.G., Sun J., Singhal S., et al. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol Ther 2010, 18:1947-1959.
85. Stevenson J.P., Kindler H.L., Papasavvas E., et al. Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients. Oncoimmunology 2013, 2(8):e26218.